Previous 10 | Next 10 |
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
Last week, Reata Pharmaceuticals (NASDAQ: RETA) closed its secondary offering, raising a whopping $505 million by selling shares at $183 per share, tripling the $240 million nest egg the biotech had at the end of the third quarter. Technically, the company didn't need to raise capital right...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
A person can be educated and still be stupid, and a wise man can have no education at all. " - Jennifer A. Nielsen, The False Prince Today, we check back in on a midcap biotech stock that has had an amazing run since we said to ' buy the dip ' when the stock traded at $20 back in March of...
PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 ...
UCB SA ( OTCPK:UCBJF ) announces the successful outcome of a second Phase 3 clinical trial, BE READY , evaluating IL-17A/IL-17F inhibitor bimekizumab in adults with moderate-to-severe plaque psoriasis. More news on: UCB SA, Eli Lilly and Company, Seneca Biopharma, Inc., Healthcare stock...
Reata Pharmaceuticals ( RETA +3.7% ) price s upsized underwritten public offering of 2.4M from 2M class A shares at $183/per share. More news on: Reata Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A com...
NextCure is down after trial data NextCure ( NXTC ) is a recently IPO-ed small cap that has come under my radar mainly because of its tremendous rise after the IPO lock-up period. That is a very good sign; it basically shows the confidence insiders must have on the stock, since they did not ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023